- Gastrointestinal Hormones
- Accession Number
HORMONES secreted by the gastrointestinal mucosa that affect the timing or the quality of secretion of digestive enzymes, and regulate the motor activity of the digestive system organs.
Drug Drug Description Glucagon A form of recombinant glucagon used to treat hypoglycemia in diabetes mellitus and as a part of gastrointestinal imaging procedures. Pentagastrin A gastrin-like molecule used as a diagnostic aid for the evaluation of gastric acid secretory function, gastric hypersecretion, and Zollinger-Ellison tumors. Liraglutide A GLP-1 analog used in the management of type 2 diabetes mellitus and prevention of cardiovascular complications associated with diabetes. Cholecystokinin For use as a diagnostic aid for evaluation of gallbladder disorders. It is also used in conjunction with secretin in pancreatic insufficiency . Dulaglutide A GLP-1 agonist used to manage type 2 diabetes mellitus. Semaglutide A glucagon-like peptide 1 receptor agonist used to improve glycemic control in type 2 diabetes mellitus. Nepidermin Not Annotated Secretin human A secretin hormone used to stimulate pancreatic or gastric secretions to diagnose exocrine pancreas dysfunction, gastrinoma, and abnormalities in the bile and pancreatic ducts. Gastric inhibitory polypeptide Gastric inhibitory polypeptide is under investigation in clinical trial NCT03081676 (The Effect of GIP and GLP-1 on Insulin and Glucagon Secretion in Patients With HNF1A-diabetes Treated With or Without Sulphonylurea). Tirzepatide A dual GIP and GLP-1 receptor agonist used for the treatment of type II diabetes in adults as an adjunct to diet and exercise. G17DT Immunogen Intended for the treatment of various forms of cancer. Peptide YY (3-36) Investigated for use/treatment in metabolic disease and obesity. rGLP-1 Investigated for use/treatment in congestive heart failure and diabetes mellitus type 2. Aviptadil Not Annotated Teduglutide A glucagon-like peptide-2 (GLP-2) analog used to treat patients with Short Bowel Syndrome (SBS) who require parenteral nutritional support. Albiglutide A GLP-1 agonist used to manage type 2 diabetes mellitus. Sincalide A diagnostic agent used to stimulate gallbladder contraction or pancreatic secretion during diagnostic tests, and accelerate fluoroscopy and x-ray examination of the intestinal tract. Taspoglutide Taspoglutide is a pharmaceutical drug, a glucagon-like peptide-1 agonist (GLP-1 agonist), under investigation for treatment of type 2 diabetes being codeveloped by Ipsen and Roche. In September 2010 Roche halted... Beinaglutide Beinaglutide is under investigation in clinical trial NCT03829891 (Study for Beinaglutide Versus Glargine Therapy in Glycemic Variability of Type 2 Diabetes Mellitus). BPI-3016 BPI-3016 is under investigation in clinical trial NCT03188848 (Dose Escalating Study of BPI-3016 in Healthy Subjects). Vasomera Not Available TP-3654 Not Annotated Peptide YY (1-36) Not Available Vasoactive intestinal peptide Not Annotated
- Drugs & Drug Targets